Recent advances in the production of potent fibrinolytic materials of human origin1 have resulted in their increasing administration to patients with thromboembolic disorders.The doses of these materials which have been recommended have been somewhat arbitrary, since they are based on clinical trials under circumstances where the results of the trials have been difficult to assay, as is generally true in patients with thromboembolism.2 In only a few of the trials has an effort been made to correlate clinical results with peripheral blood fibrinolytic activity.2,3 This has been largely due to a lack of uniformity of methods for determining this activity.3 It has also been the result of the contention that administered plasminogen and activator disappear rapidly from the peripheral blood and join themselves to the clot, where they continue to exert fibrinolytic effects in the absence of demonstrable activity in the peripheral blood.4
OUCHI H, BELKO JS, WARREN R. Fibrinolysin Therapy: Critical Thrombolytic Dosages and Blood Levels. Arch Surg. 1961;82(1):88–96. doi:10.1001/archsurg.1961.01300070092012
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: